Recognition and Management of Mitragynine Pseudoindoxyl Withdrawal

A recent case report describes a hospitalized 44-year-old man with a long polysubstance history who presented with alcohol withdrawal alongside an opioid-type withdrawal syndrome that the authors attribute, by history, to recent daily use of mitragynine pseudoindoxyl (MP), described as occurring in the absence of other opioid use. The inpatient team tracked withdrawal severity over time and pursued a rapid buprenorphine approach described as macro-induction, alongside symptom-directed adjunctive medications. The report outlines the clinical reasoning used to recognize the syndrome and traces the induction and subsequent maintenance trajectory during the admission.

In background framing, the authors describe MP as a semi-synthetic kratom metabolite increasingly sold online and over the counter and often marketed as “kratom” or “7-OH,” noting limited human safety data and lack of FDA-approved indications. In the case narrative, the patient reported escalating MP tablet use for pain after a neck injury, followed by abrupt interruption of use for several days before hospital presentation. Alcohol and opioid-type withdrawal were tracked in parallel using Alcohol Withdrawal Symptoms (AWS) and Clinical Opiate Withdrawal Scale (COWS) scores, with gastrointestinal upset and autonomic features among the reported symptoms. This monitoring structure set the stage for a hospital-based withdrawal management strategy aligned to symptom burden.

The macro-induction protocol is detailed in the report and includes both premedication and an initial high-dose buprenorphine sequence. As documented, the team pretreated with chlorpromazine 25 mg IV and diazepam 5 mg IV, then administered buprenorphine as two 16 mg doses 30 minutes apart (32 mg total on day 1), with additional buprenorphine available PRN as 2 mg every 4 hours for COWS scores >5. During this period, the authors also report using adjunctive symptomatic medications such as clonidine and ondansetron, alongside other symptom-targeted agents. In the narrative, the early phase after buprenorphine macro‑induction is associated with a significant decrease in the patient’s reported opioid-withdrawal symptoms shortly after treatment began.

Across subsequent hospital days, the authors describe continued improvement in opioid-withdrawal symptoms with downward-trending COWS scores and progression to a stable daily buprenorphine regimen by day 4 (24 mg daily), with a later dose reduction after surgery as described in the case course. The admission was complicated by a right-hand abscess/cellulitis requiring operative management, during which the report notes a temporary discontinuation of buprenorphine followed by restart and up-titration in the postoperative period. In disposition planning, the patient expressed interest in long-acting injectable buprenorphine for maintenance, but left before dosing could be arranged. The course is presented as moving from acute symptom control toward an intended maintenance linkage that was not completed during hospitalization.

In discussion, the authors describe this as their first documented case of suspected MP withdrawal managed with buprenorphine macro-induction and outline their pharmacologic rationale for macro-induction in the setting of high-potency opioid receptor agonists, alongside a summary of prior literature they cite on macro-induction safety in other settings. They also note a case-specific limitation: MP exposure was not biochemically confirmed, and the attribution relied on patient report in the context of available testing.

Key Takeaways:

• The case report describes an opioid-type withdrawal syndrome attributed by history to mitragynine pseudoindoxyl use, with concurrent alcohol withdrawal tracked using AWS and opioid withdrawal tracked using COWS.
• The authors document a single-day buprenorphine macro-induction with specified premedications and PRN dosing rules, alongside adjunctive symptom management (including clonidine and ondansetron) during induction.
• The clinical course includes reported symptom improvement and stabilization on daily buprenorphine with later perioperative dose changes; the patient voiced interest in long-acting injectable buprenorphine but left before initiation, and the authors note lack of biochemical confirmation of MP exposure.